1. 2022
  2. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

    Wieske, L., van Dam, K. P. J., Steenhuis, M., Stalman, E. W., Kummer, L. Y. L., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., Wolbink, G. J., van der Kooi, A. J., Raaphorst, J., Löwenberg, M., Takkenberg, R. B., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., & 56 othersBosma, A. L., Hilhorst, M. L., Vegting, Y., Bemelman, F. J., Voskuyl, A. E., Broens, B., Sanchez, A. P., van Els, C. C. A. C. M., de Wit, J., Rutgers, A., de Leeuw, K., Horváth, B., Verschuuren, J. J. G. M., Ruiter, A. M., van Ouwerkerk, L., van der Woude, D., Allaart, R. C. F., Teng, Y. K. O., van Paassen, P., Busch, M. H., Jallah, P. B. P., Brusse, E., van Doorn, P. A., Baars, A. E., Hijnen, D. J., Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Keijzer, S., Keijser, J. B. D., Boogaard, A., Cristianawati, O., ten Brinke, A., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., Kuijpers, T. W., Rispens, T., Eftimov, F., T2B! immunity against SARS-CoV-2 study group, de Jongh, R., van de Sandt, C. E., Kuijper, L., Duurland, M., Hagen, R. R., van den Dijssel, J., Kreher, C., Bos, A., Palomares Cabeza, V., Konijn, V. A. L., Elias, G., Vallejo, J. G., van Gils, M. J., Ashhurst, T. M., Nejentsev, S. & Mirfazeli, E. S., 1 May 2022, In: The Lancet Rheumatology. 4, 5, p. e338-e350

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?

    van Kempen, Z. L. E., Wieske, L., Stalman, E. W., Kummer, L. Y. L., van Dam, P. J., Volkers, A. G., Boekel, L., Toorop, A. A., Strijbis, E. M. M., Tas, S. W., Wolbink, G. J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N. J. M., Steenhuis, M., Kuijpers, T. W., van Ham, S. M., Rispens, T., Eftimov, F., & 1 othersKillestein, J., 1 Jan 2022, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 57, 103416.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273

    On behalf of the T2B immunity against SARS-CoV-2 study group, 2022, In: eLife. 11, e77969.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. 2021
  6. Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients

    van Kempen, Z. L. E., Killestein, J. & Hartung, H-P., 1 Dec 2021, In: Multiple sclerosis (Houndmills, Basingstoke, England). 27, 14, p. 2123-2125 3 p.

    Research output: Contribution to journalEditorialAcademicpeer-review

  7. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

    Boekel, L., Steenhuis, M., Hooijberg, F., Besten, Y. R., van Kempen, Z. L. E., Kummer, L. Y., van Dam, K. P. J., Stalman, E. W., Vogelzang, E. H., Cristianawati, O., Keijzer, S., Vidarsson, G., Voskuyl, A. E., Wieske, L., Eftimov, F., van Vollenhoven, R., Kuijpers, T. W., van Ham, S. M., Tas, S. W., Killestein, J., & 4 othersBoers, M., Nurmohamed, M. T., Rispens, T. & Wolbink, G., 1 Nov 2021, In: The Lancet Rheumatology. 3, 11, p. e778-e788

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Response to letter ‘Lymphocyte counts and the risk of COVID-19 in people with MS’

    Loonstra, F. C., van Kempen, Z. L. E., Strijbis, E. M., Killestein, J., Hoitsma, E. & Mostert, J. P., Sep 2021, In: Multiple sclerosis (Houndmills, Basingstoke, England). 27, 10, p. 1626-1627 2 p.

    Research output: Contribution to journalComment/Letter to the editorAcademic

  9. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases

    Boekel, L., Kummer, L. Y., van Dam, K. P. J., Hooijberg, F., van Kempen, Z., Vogelzang, E. H., Wieske, L., Eftimov, F., van Vollenhoven, R., Kuijpers, T. W., van Ham, S. M., Tas, S. W., Killestein, J., Boers, M., Nurmohamed, M. T., Rispens, T. & Wolbink, G., 1 Aug 2021, In: The Lancet Rheumatology. 3, 8, p. e542-e545

    Research output: Contribution to journalComment/Letter to the editorAcademic

  10. Natalizumab discontinuation in a Dutch real-world cohort

    Coerver, E. M. E., Wessels, M. H. J., van Lierop, Z. Y. G., van Kempen, Z. L. E., Killestein, J. & Strijbis, E. M. M., 1 Jul 2021, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 52, 102974.

    Research output: Contribution to journalComment/Letter to the editorAcademic

  11. SARS-CoV-2 Antibodies in Adult Patients with Multiple Sclerosis in the Amsterdam MS Cohort

    van Kempen, Z. L. E., Strijbis, E. M. M., Al, M. M. C. T., Steenhuis, M., Uitdehaag, B. M. J., Rispens, T. & Killestein, J., Jul 2021, In: JAMA Neurology. 78, 7, p. 880-882 3 p.

    Research output: Contribution to journalComment/Letter to the editorAcademic

  12. Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients

    van Kempen, Z. L. E., van Rossum, J. A., Hoogervorst, E., Strijbis, E., Toorop, A., Bosscha, M. I., Frequin, S., Dam-van Loon, N. T., Wattjes, M. P., Murk, J-L., Killestein, J. & Uitdehaag, B. M. J., 1 May 2021, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 50, 102838.

    Research output: Contribution to journalComment/Letter to the editorAcademic

ID: 97640